Product Reports Resources Pricing Login Book a demo

Chengdu Maxvax Biotechnology

Biotech & Life Sciences · Chengdu, China · Founded 2016

CDMO for plasmid DNA, mRNA, and proteins.

Investors

14 investors on Chengdu Maxvax Biotechnology's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage
Korea Investment Partners
Sherpa Venture Partners
Hillhouse Capital
Series B+ 11 investors entered at this stage
Fangshizhen Capital
IDG Capital
Qianhai FOF
Xinshang Capital
GF Qianhe
Guohai Innovative CCI Capital
Sherpa Investment
Gortune Investment
China Life Private Equity Investment
Shenzhen Capital Group
Shanghai Hankang Private Equity Fund Management

Ownership

Who owns Chengdu Maxvax Biotechnology

Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.

34.7% Founders

Some investors are hidden on this public profile. “Other / undisclosed” is the 4.8% not attributed to a named shareholder. See the full cap table on Dealroom →

Global footprint

Where Chengdu Maxvax Biotechnology has talent and traffic

Workforce by country
🇨🇳 China · Chengdu HQ
Book a demo for the full country breakdown
Web traffic by country
130 monthly visits
across markets
🇺🇸 United States76.9%
Top 1 markets shown

Talent graph

The shape of Chengdu Maxvax Biotechnology's talent

Dealroom maps Chengdu Maxvax Biotechnology's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Chengdu Maxvax Biotechnology's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$3M patent portfolio · 143 active families

Estimated portfolio value
$3M
0.32% of valuation · 17.1× smaller than top peer Akeso Biopharma ($59M)
143 active patent families

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Chengdu Maxvax Biotechnology

An AI-synthesized read of the highest-engagement posts about Chengdu Maxvax Biotechnology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Chengdu Maxvax Biotechnology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.